Cyclodextrins as pharmaceutical solubilizers
Tóm tắt
Từ khóa
Tài liệu tham khảo
Villiers, 1891, Sur la fermentation de la fécule par l'action du ferment butyrique, Compt. Rend. Acad. Sci., 112, 536
Loftsson, 2007, Cyclodextrins and their pharmaceutical applications, Int. J. Pharm., 329, 1, 10.1016/j.ijpharm.2006.10.044
Schardinger, 1903, Über Thermophile Bakterien aus verschiedenen Speisen und Milch, sowie über einige Umsetzungsprodukte derselben in kohlenhydrathaltigen Nährlösungen, darunter krystallisierte Polysaccharide (Dextrine) aus Stärke, Z. Unters. Nahr.- Genussm., 6, 865, 10.1007/BF02067497
Schardinger, 1911, Bildung kristallisierter Polysaccharide (Dextrine) aus Stärkekleister durch Microben, Zentralbl. Bakteriol. Parasitenkd. Abt. II, 29, 188
Freudenberg, 1935, Über Schardinger Dextrine aus Stärke Liebigs, Ann. Chem., 518, 102, 10.1002/jlac.19355180107
Larsen, 2002, Large cyclodextrins, J. Incl. Phenom. Macrocycl. Chem., 43, 1, 10.1023/A:1020494503684
Ueda, 2006, Large-ring cyclodextrins, 370
Cramer, 1954
1999, vol. 36
Oguma, 2003, Production of cyclodextrin and its applications, Trends Glycosci. Glycotechnol., 15, 91, 10.4052/tigg.15.91
Uekama, 2006, Recent aspects of cyclodextrin-based drug delivery systems, J. Incl. Phenom. Macrocycl. Chem., 56, 3, 10.1007/s10847-006-9052-y
Strickley, 2004, Solubilizing excipients in oral and injectable formulations, Pharm. Res., 21, 201, 10.1023/B:PHAM.0000016235.32639.23
Loftsson, 2004, Role of cyclodextrins in improving oral drug delivery, Am. J. Drug Deliv., 2, 261, 10.2165/00137696-200402040-00006
Davis, 2004, Cyclodextrin-based pharmaceutics: past, present and future, Nat. Rev., Drug Discov., 3, 1023, 10.1038/nrd1576
Avdeef, 2007, Solubility-excipient classification gradient maps, Pharm. Res., 24, 530, 10.1007/s11095-006-9169-0
Kim, 2004, Solubility enhancers for oral drug delivery, Am. J. Drug Deliv., 2, 113, 10.2165/00137696-200402020-00004
Loftsson, 2005, Cyclodextrins in drug delivery, Expert Opin. Drug Deliv., 2, 335, 10.1517/17425247.2.1.335
Szejtli, 2005, Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins, Eur. J. Pharm. Biopharm., 61, 115, 10.1016/j.ejpb.2005.05.006
Lantz, 2006, Estimation of association constants between oral malodor components and various native and derivatized cyclodextrins, Anal. Chim. Acta, 557, 184, 10.1016/j.aca.2005.10.005
Loftsson, 1996, Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization, J. Pharm. Sci., 85, 1017, 10.1021/js950534b
Szejtli, 1982
Szejtli, 1988
Stella, 1997, Cyclodextrins: their future in drug formulation and delivery, Pharm. Res., 14, 556, 10.1023/A:1012136608249
Frömming, 1994
Winkler, 2000, Hydration of β-cyclodextrin: a molecular dynamics simulation study, J. Comput. Aided Mol. Des., 14, 659, 10.1023/A:1008155230143
Bone, 2006, Dielectric studies of water clusters in cyclodextrins: relevance to the transition between slow and fast forms, J. Phys. Chem., B, 110, 20609, 10.1021/jp063811j
Hakkarainen, 2005, 1H NMR studies on the hydrogen-bonding network in mono-altro-β-cyclodextrin and its complex with adamantane-1-carboxylic acid, Carbohydr. Res., 340, 1539, 10.1016/j.carres.2005.03.016
Lichtenthaler, 1996, On the hydrophobic characteristics of cyclodextrins: computer-aided visualization of molecular lipophilicity patterns, Liebigs Ann. Chem., 27, 10.1002/jlac.199619960105
Bender, 1978
Schmid, 1989, Cyclodextrin glycosyltransferase production; yield enhancement by overexpression of cloned genes, Tibtech, 7, 244, 10.1016/0167-7799(89)90015-2
Schmid, 1991, Preparation and application of γ-cyclodextrin, 25
Sicard, 1987, Biosynthesis of cycloglycosyltransferase and obtention of enzymatic reaction products, 77
Rajewski, 1996, Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery, J. Pharm. Sci., 85, 1142, 10.1021/js960075u
Irie, 1997, Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation, J. Pharm. Sci., 86, 147, 10.1021/js960213f
Thompson, 1997, Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals, Crit. Rev. Ther. Drug Carr. Syst., 14, 1, 10.1615/CritRevTherDrugCarrierSyst.v14.i1.10
2002, vol. 909, 41
Lina, 2004, Subchronic oral toxicity studies with α-cyclodextrin in rats, Regul. Toxicol. Pharmacol., 39, S14, 10.1016/j.yrtph.2004.05.006
Lina, 2004, Subchronic (13-week) oral toxicity study of α-cyclodextrin in dogs, Regul. Toxicol. Pharmacol., 39, S27, 10.1016/j.yrtph.2004.05.005
Bellringer, 1995, β-Cyclodextrin: 52-week toxicity studies in the rat and dog, Food Chem. Toxicol., 367, 10.1016/0278-6915(94)00149-I
Munro, 2004, Safety assessment of γ-cyclodextrin, Regul. Toxicol. Pharmacol., 39, S3, 10.1016/j.yrtph.2004.05.008
Koutsou, 1999, Gastrointestinal tolerance of γ-cyclodextrin in humans, Food Addit. Contam., 16, 313, 10.1080/026520399283984
Gould, 2005, 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review, Food Chem. Toxicol., 43, 1451, 10.1016/j.fct.2005.03.007
M.E. Brewster, C. Mackie, A. Lampo, M. Noppe, T. Loftsson, The use of solubilizing excipients and approaches to generate toxicology vehicles for contemporary drug pipelines, in: P. Augustijns and M.E. Brewster (Eds.), Solvent systems and their selection in pharmaceutics and biopharmaceutics, American Association of Pharmaceutical Scientists and Springer: New York, (2007), pp. 221-256.
2003, Physician’s Desk Reference
1997, Toxicological data
Uekama, 2004, Design and evaluation of cyclodextrin-based drug formulation, Chem. Pharm. Bull., 52, 900, 10.1248/cpb.52.900
Antlsperger, 1996, Toxicological comparison of cyclodextrins, 149
Hirayama, 1999, Cyclodextrin-based controlled release systems, Adv. Drug Deliv. Rev., 36, 125, 10.1016/S0169-409X(98)00058-1
Challa, 2005, Cyclodextrin in drug delivery: an updated review, AAPS PharmSciTech, 6, E329, 10.1208/pt060243
Vromans, 1989, Mechanism of dissolution of drug-cyclodextrin complexes. A pragmatic approach, Acta Pharm. Technol., 35, 250
Amidon, 1995, Theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413, 10.1023/A:1016212804288
Dressman, 1998, Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms, Pharm. Res., 15, 11, 10.1023/A:1011984216775
Yu, 2002, Biopharmaceutics classification system: the scientific basis for biowaiver extensions, Pharm. Res., 19, 921, 10.1023/A:1016473601633
Loftsson, 2002, Cyclodextrins and the biopharmaceutical classification system of drugs, J. Incl. Phenom. Macrocycl. Chem., 44, 63, 10.1023/A:1023088423667
Pitha, 1992, Preparation of drug-hydroxypropyl cyclodextrin complexes by a method using ethanol or aqueous ammonium hydroxide as cosolubilizers, Int. J. Pharm., 80, 253, 10.1016/0378-5173(92)90282-7
Pitha, 1992, Effect of ethanol on formation of inclusion complexes of hydroxypropyl cyclodextrin with testosterone or with methyl orange, Int. J. Pharm., 80, 243, 10.1016/0378-5173(92)90281-6
Stella, 1999, Mechanisms of drug release from cyclodextrin complexes, Adv. Drug Deliv. Rev., 36, 3, 10.1016/S0169-409X(98)00052-0
Connors, 1995, Population characteristics of cyclodextrin complex stabilities in aqueous solution, J. Pharm. Sci., 84, 843, 10.1002/jps.2600840712
Connors, 1997, The stability of cyclodextrin complexes in solution, Chem. Rev., 97, 1325, 10.1021/cr960371r
Rao, 2003, When can cyclodextrins be considered for solubilizing purposes?, J. Pharm. Sci., 92, 927, 10.1002/jps.10341
Aoyama, 1992, Host-guest complexation of oligosaccharides: interaction of maltodextrins with hydrophobic fluorescence probes in water, Tetrahedron Lett., 33, 3775, 10.1016/0040-4039(92)80022-C
1991, vol. 3
Loftsson, 1996, The effect of water-soluble polymers on aqueous solubility of drugs, Int. J. Pharm., 127, 293, 10.1016/0378-5173(95)04207-5
Gabelica, 2002, On the specificity of cyclodextrin complexes detected by electrospray mass spectrometry, J. Am. Soc. Mass Spectrom., 13, 946, 10.1016/S1044-0305(02)00416-6
Correia, 2002, Study of inclusion complexes of acridine with β- and (2,6-di-O-methyl)-β-cyclodextrin by use of solubility diagrams and NMR spectroscopy, J. Phys. Org. Chem., 15, 647, 10.1002/poc.528
Andronati, 1996, Inclusion compounds of psychotropic agents and cyclodextrins, J. Incl. Phenom. Macrocycl. Chem., 24, 175, 10.1007/BF01053430
Loftsson, 2002, Self-association and cyclodextrin solubilization of drugs, J. Pharm. Sci., 91, 2307, 10.1002/jps.10226
Loftsson, 2004, Self-association of cyclodextrins and cyclodextrin complexes, J. Pharm. Sci., 93, 1091, 10.1002/jps.20047
Chadha, 2004, Account of analytical techniques employed for the determination of thermodynamics of inclusion complexation of drugs with cyclodextrins, J. Sci. Ind. Res., 63, 211
Higuchi, 1965, vol. 4, 117
Connons, 1996, Measurement of cyclodextrin complex stability constants, vol. 3, 205
Brewster, 1999, Complexation — use of cyclodextrins to improve pharmaceutical properties of intramuscular formulations, 307
Loftsson, 2005, Evaluation of cyclodextrin solubilization of drugs, Int. J. Pharm., 302, 18, 10.1016/j.ijpharm.2005.05.042
Higuchi, 1970, Binding specificity between small organic solutes in aqueous solution: classification of some solutes into two groups according to binding tendencies, J. Pharm. Sci., 59, 1601, 10.1002/jps.2600591112
Peeters, 2002, Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4 and 7, J. Pharm. Sci., 91, 1414, 10.1002/jps.10126
Pourmokhtar, 2005, Enhanced stability of sulfamethazole and trimethoprim against oxidation using hydroxypropyl-β-cyclodextrin, Pharmazie, 60, 837
Chen, 1996, Effect of hydroxypropyl-β-cyclodextrin on the solubility, photostability and in-vivo permeability of alkannin/shikonin enantiomers, Int. J. Pharm., 141, 171, 10.1016/0378-5173(96)04634-0
Bekers, 1990, Inclusion complexation of doxorubicin and daunorubicin with cyclodextrins, J. Pharm. Biomed. Anal., 8, 671, 10.1016/0731-7085(90)80100-4
Brewster, 1991, Effect of various cyclodextrins on solution stability and dissolution rate of doxorubicin hydrochloride, Int. J. Pharm., 79, 289, 10.1016/0378-5173(92)90121-H
Cervero, 2000, Inclusion complexes of dimethyl 2,6-naphthalenedicarboxylate with α- and β-cyclodextrins in aqueous medium: thermodynamics and molecular mechanics study, J. Phys. Chem., B, 104, 1572, 10.1021/jp993418w
Mohanty, 2006, Host-guest complexation of neutral red with macrocyclic host molecules: contrasting pKa shifts and binding affinities for cucurbit[7]uril and β-cyclodextrin, J. Phys. Chem., B, 110, 5132, 10.1021/jp056411p
Yang, 2000, The performance of the Benesi-Hildebrand method in measuring the binding constants of the cyclodextrin complexation, Anal. Sci., 16, 537, 10.2116/analsci.16.537
Crane, 2002, Cyclodextrin inclusion complexes with a solvatochrome fluorescent probe, J. Chem. Educ., 79, 1261, 10.1021/ed079p1261
Abdel-Shafi, 2007, Spectroscopic studies on the inclusion complex of 2-naphtol-6-sulfonate with β-cyclodextrin, Spectrochim. Acta, Part A: Mol. Biomol. Spectrosc., 66A, 732, 10.1016/j.saa.2006.04.018
Schneider, 1993, Supermolecular Chemistry. 36. NMR spectroscopy and molecular-mechanics calculations in supermolecular chemistry, Rec. Trav. Chem., 112, 412, 10.1002/recl.19931120618
Ganza-Gonzalez, 1994, A proton nuclear magnetic resonance study of the inclusion of naproxen with β-cyclodextrin, Int. J. Pharm., 106, 179, 10.1016/0378-5173(94)90001-9
Piel, 2001, A nuclear magnetic resonance study of the miconazole-β-cyclodextrin inclusion complex in an acidic medium: determination of the structure and stability constant, STP Pharm. Sci., 11, 235
Masson, 2003, Estimation of 19F-NMR as a tool for investigation of drug-cyclodextrin complexes, Drug Dev. Ind. Pharm., 29, 107, 10.1081/DDC-120016689
Polyakov, 2004, Inclusion complexes of carotenoids with cyclodextrins: 1H-NMR, EPR and optical studies, Free Radic. Biol. Med., 36, 872, 10.1016/j.freeradbiomed.2003.12.009
Hofler, 1996, Determination of binding energies between cyclodextrins and aromatic guest molecules by calorimetry, J. Incl. Phenom. Macrocycl. Chem., 25, 81, 10.1007/BF01041541
Wenz, 1998, Inclusion of pharmaceutical drugs in cyclodextrins as measured by titration microcalorimetry, Polym. Prepr., 39, 202
Li, 1983, Complex formation between α-cyclodextrin and 4-substituted phenols studies by potentiometric and competitive spectrophotometric methods, J. Pharm. Sci., 72, 1333, 10.1002/jps.2600721124
Davies, 1998, Stability constants of α-cyclodextrin complexes of para-substituted aromatic ketones in aqueous solution, J. Chem. Soc., Perkin Trans., 2, 193, 10.1039/a701470h
Masson, 2005, Investigation of drug-cyclodextrin complexes by a phase-distribution method: some theoretical and practical consideration, Chem. Pharm. Bull., 53, 958, 10.1248/cpb.53.958
Moeder, 1996, Determination of stoichiometric coefficients and apparent stability constants for α- and β-CD complexes of terpenes using reversed-phase liquid chromatography, J. Chromatogr., A, 736, 1, 10.1016/0021-9673(95)01276-1
Loukas, 1994, γ-Cyclodextrin complex of a new organophosphate insecticide. Determination of stability constant with HPLC, J. Agric. Food Chem., 42, 944, 10.1021/jf00040a020
Durham, 1994, Molecular modeling of the inclusion complexes between β-cyclodextrin and (R)/(S)-methylphenobarbitone and its application to HPLC, Chirality, 6, 240, 10.1002/chir.530060405
Fukahori, 2004, Ultrasonic relaxation due to inclusion complex of amino acid by β-cyclodextrin in aqueous solution, J. Acoust. Soc. Am., 115, 2325, 10.1121/1.1695432
Cirri, 2005, Determination of stability constant values of flurbiprofen-cyclodextrin complexes using different techniques, J. Pharm. Biomed. Anal., 37, 995, 10.1016/j.jpba.2004.09.044
Landy, 2007, Development of a competitive continuous variation plot for the determination of inclusion compound stoichiometry, J. Incl. Phenom. Macrocycl. Chem., 57, 409, 10.1007/s10847-006-9226-7
Loukas, 1997, Measurement of molecular association in drug: cyclodextrin inclusion complexes with improved 1H NMR studies, J. Pharm. Pharmacol., 49, 944, 10.1111/j.2042-7158.1997.tb06021.x
2006
Ross, 1996, Thermodynamics of hydrogen bond and hydrophobic interactions in cyclodextrin complexes, Biophys. J., 71, 2144, 10.1016/S0006-3495(96)79415-8
Tong, 1991, Microcalorimetric investigation of the complexation between 2-hydroxypropyl-β-cyclodextrin and amine drugs with diphenylmethyl functionality, J. Pharm. Biomed. Anal., 9, 1139, 10.1016/0731-7085(91)80056-F
Gelb, 1982, Cycloamylose complexation of organic anions, J. Phys. Chem., 87, 3349, 10.1021/j100240a033
Gelb, 1981, Binding mechanisms in cyclohexaamylose complexes, J. Am. Chem. Soc., 103, 1750, 10.1021/ja00397a027
Kurihara, 1990, Improvement of some pharmaceutical properties of cloprost by β- and γ-cyclodextrin complexation, J. Incl. Phenom. Mol. Recognit. Chem., 8, 363, 10.1007/BF01041192
Matsuyama, 1987, Thermodynamics of binding of aromatic amino acids to α-, β- and γ-cyclodextrin, Drug Dev. Ind. Pharm., 13, 2687, 10.3109/03639048709022084
Alvira, 2000, Factors influencing β-cyclodextrin inclusion complex formation, Recent Res. Dev. Chem. Phys., 1, 89
Marques, 1994, Application of cyclodextrins. Thermodynamic aspects of cyclodextrin complexes, Rev. Port. Farm., 44, 85
Liu, 1999, Novel prediction for the driving force and guest orientation in the complexation of α- and β-cyclodextrin with benzene derivatives, J. Phys. Chem., B, 103, 3461, 10.1021/jp984545f
Pinjari, 2006, Molecular electrostatic potentials and hydrogen bonding in α-, β-, and γ-cyclodextrins, J. Phys. Chem., A, 110, 13073, 10.1021/jp065169z
Bergeron, 1984, Cycloamylose-substrate binding, 391
Liu, 2002, The driving forces in the inclusion complexation of cyclodextrins, J. Incl. Phenom. Macrocycl. Chem., 42, 1, 10.1023/A:1014520830813
Liu, 1999, Regression analysis for the host-guest interaction of β-cyclodextrin with mono- and 1, 4-disubstituted benzenes, J. Incl. Phenom. Macrocycl. Chem., 34, 413, 10.1023/A:1008069209462
Magnusdottir, 2002, Self-association and cyclodextrin solubilization of NSAID's, J. Incl. Phenom. Macrocycl. Chem., 44, 213, 10.1023/A:1023079322024
Loftsson, 2003, The effect of organic salts on the cyclodextrin solubilization of drugs, Int. J. Pharm., 262, 101, 10.1016/S0378-5173(03)00334-X
Loftsson, 1999, Methods to enhance the complexation efficiency of cyclodextrins, STP Pharm. Sci., 9, 237
Loftsson, 2004, The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs, J. Drug Del. Sci. Tech., 14, 35, 10.1016/S1773-2247(04)50003-5
Jug, 2004, Hydroxy methylcellulose microspheres with piroxicam and piroxicam-hydroxypropyl-β-cyclodextrin inclusion complex, Pharmazie, 59, 686
Ribeiro, 2003, Physicochemical investigations on the effects of water-soluble polymers on vinpocetine complexation with β-cyclodextrin and its sulfobutyl ether derivative in solution and solid state, Eur. J. Pharm. Sci., 20, 253, 10.1016/S0928-0987(03)00199-4
Cirri, 2006, Simultaneous effect of cyclodextrin complexation, pH and hydrophilic polymers on naproxen solubilization, J. Pharm. Biomed. Anal., 42, 126, 10.1016/j.jpba.2005.11.029
Valero, 2003, Ternary naproxen:β-cyclodextrin:polyethylene glycol complex formation, Int. J. Pharm., 265, 141, 10.1016/j.ijpharm.2003.07.003
Jug, 2004, Multicomponent complexes of piroxicam with cyclodextrin and hydroxypropyl methylcellulose, Drug Dev. Ind. Pharm., 30, 1051, 10.1081/DDC-200040245
Ribeiro, 2003, Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether β-cyclodextrin binary and ternary complexes, Chem. Pharm. Bull., 51, 914, 10.1248/cpb.51.914
Krishnamoorthy, 1996, Complexation of weak acids and basis with cyclodextrins: Effects of substrate ionization on the estimation and interpretation of association constants, Int. J. Pharm. Adv., 1, 330
Redenti, 2001, Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications, J. Pharm. Sci., 90, 979, 10.1002/jps.1050
Redenti, 2000, Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications, J. Pharm. Sci., 89, 1, 10.1002/(SICI)1520-6017(200001)89:1<1::AID-JPS1>3.0.CO;2-W
Ribeiro, 2005, Multicomponent complex formation between vinpocetine, cyclodextrins, tartaric acid and water-soluble polymers monitored by NMR and solubility studies, Eur. J. Pharm. Sci., 24, 1, 10.1016/j.ejps.2004.09.003
Loftsson, 2004, Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs, Pharmazie, 59, 25
Mura, 2003, Ternary systems of naproxen with hydroxypropyl-β-cyclodextrin and amino acids, Int. J. Pharm., 260, 293, 10.1016/S0378-5173(03)00265-5
Li, 1998, Combined effect of complexation and pH on solubilization, J. Pharm. Sci., 87, 1535, 10.1021/js9801889
Loftsson, 2007, The complexation efficiency, J. Incl. Phenom. Macrocycl. Chem., 57, 545, 10.1007/s10847-006-9247-2
Usui, 1997, Inhibitory effects of water-soluble polymers on precipitation of RS-8359, Int. J. Pharm., 154, 59, 10.1016/S0378-5173(97)00129-4
Attwood, 1983, Surfactant systems, 361
Myers, 1988, 142
Malmsten, 2002
Loftsson, 1998, The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin, Int. J. Pharm., 163, 115, 10.1016/S0378-5173(97)00371-2
Valero, 2004, Naproxen:hydroxypropyl-β-cyclodextrin:polyvinylpyrrolidone ternary complex formation, J. Incl. Phenom. Macrocycl. Chem., 48, 157, 10.1023/B:JIPH.0000022522.84387.db
Yamakawa, 2003, Liquid formulation of a novel non-fluorinated topical quinolone, T-3912, utilizing the synergic solubilizing effect of the combined use of magnesium ions and hydroxypropyl-β-cyclodextrin, J. Control. Release, 86, 101, 10.1016/S0168-3659(02)00367-X
Harada, 1997, Design and construction of supramolecular architectures consisting of cyclodextrins and polymers, Adv. Polym. Sci., 133, 141, 10.1007/3-540-68442-5_4
Torres-Labandeira, 1990, Oversaturated solutions of drug in hydroxypropylcyclodextrins: parenteral preparation of pancratistatin, J. Pharm. Sci., 80, 384, 10.1002/jps.2600800421
Brewster, 2007, Solubilization of itraconazole as a function of cyclodextrin structural space, J. Incl. Phenom. Macrocycl. Chem., 57, 561, 10.1007/s10847-006-9249-0
Xiang, 2002, Stable supersaturated aqueous solution of Silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified β-cyclodextrin, Pharm. Res., 19, 1215, 10.1023/A:1019862629357
Wang, 1993, Release characteristics of nifedipine from 2-hydroxypropyl-β-cyclodextrin complex during storage and its modification of hybridizing polyvinylpyrrolidone K-30, Chem. Pharm. Bull., 41, 1822, 10.1248/cpb.41.1822
Uekama, 1992, Inhibitory effect of 2-hydroxypropyl-β-cyclodextrin on crystal-growth of nifedipine during storage: superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30, J. Pharm. Pharmacol., 44, 73, 10.1111/j.2042-7158.1992.tb03564.x
Jaconson, 1999, Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity — drug supersaturation, toxicity to TR166 cells and release from a delivery system, Eur. J. Pharm. Biopharm., 48, 217, 10.1016/S0939-6411(99)00043-0
Castillo, 1999, Preparation and characterization of albendazole β-cyclodextrin complexes, Drug Dev. Ind. Pharm., 25, 1241, 10.1081/DDC-100102294
Pedersen, 1998, A genuine clotrimazole γ-cyclodextrin inclusion complex-isolation, antimycotic activity, toxicity and unusual dissolution rate, Int. J. Pharm., 176, 121, 10.1016/S0378-5173(98)00310-X
Pedersen, 1998, An econazole β-cyclodextrin inclusion complex: an unusual dissolution rate, supersaturation and biological efficacy example, Int. J. Pharm., 165, 57, 10.1016/S0378-5173(97)00431-6
Pedersen, 1999, Cyclodextrin inclusion complexes of miconazole and econazole – isolation, toxicity on human cells and confirmation of a new interpretation of the drug supersaturation phenomenon, Drug Dev. Ind. Pharm., 25, 463, 10.1081/DDC-100102196
Leichtman, 2007, Impact of antinucleants on transdermal delivery of testosterone from a spray, J. Pharm. Sci., 96, 84, 10.1002/jps.20670
Dias, 2003, The effect of β-cyclodextrin on the permeation of diclofenac from supersaturated solutions, Int. J. Pharm., 263, 173, 10.1016/S0378-5173(03)00366-1
Iervolino, 2001, Penetration enhancement of ibuprofen from supersaturated solutions through human skin, Int. J. Pharm., 212, 131, 10.1016/S0378-5173(00)00603-7
Iervolino, 2000, Membrane penetration enhancement of ibuprofen using supersaturation, Int. J. Pharm., 198, 229, 10.1016/S0378-5173(00)00346-X
Macie, 1986, Crystal growth in pharmaceutical formulation, Pharm. Intl., 233
Raghvan, 2001, Crystallization of hydrocortisone acetate: influence of polymers, Int. J. Pharm., 212, 213, 10.1016/S0378-5173(00)00610-4
Raghavan, 2003, Formation and stabilization of triclosan colloidal suspension using supersaturated systems, Int. J. Pharm., 261, 153, 10.1016/S0378-5173(03)00299-0
Gao, 2004, Enhanced oral bioavailability of a poorly water-soluble drug PNU-91325 by supersaturable formulations, Drug Dev. Ind. Pharm., 30, 221, 10.1081/DDC-120028718
Terayama, 2004, Preparation of stable aqueous suspension of a hydrophobic drug with polymers, Colloids Surf., B Biointerfaces, 39, 159, 10.1016/j.colsurfb.2004.09.005
Simonelli, 1970, Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone, J. Pharm. Sci., 59, 633, 10.1002/jps.2600590512
Rodriguez-Hornedo, 1999, Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems, J. Pharm. Sci., 88, 651, 10.1021/js980490h
Yokoi, 2005, Effect of sugar esters and hydroxypropyl methylcellulose on the physicochemical stability of amorphous pivoxil in aqueous suspension, Int. J. Pharm., 290, 91, 10.1016/j.ijpharm.2004.11.020
Pedersen, 1997, The bioavailability difference between genuine cyclodextrin inclusion complexes and freeze-dried or ground drug cyclodextrin samples may be due to supersaturation differences, Drug Dev. Ind. Pharm., 23, 331, 10.3109/03639049709149812
Lipinski, 1997, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev., 23, 3, 10.1016/S0169-409X(96)00423-1
Lipinski, 2001, Avoiding investment in doomed drugs, Curr. Drug Discov., 1, 17
Prentis, 1988, Pharmaceutical innovation by seven UK-owned pharmaceutical companies, Br. J. Clin. Pharmacol., 2, 387, 10.1111/j.1365-2125.1988.tb03318.x
Kola, 2004, Can the pharmaceutical industry reduce attrition rates?, Nat. Rev., Drug Discov., 2, 711, 10.1038/nrd1470
Liu, 2000
Abdoh, 2007, Changes in the conformational structure, microscopic and macroscopic pKa's of meloxicam on complexation with natural and modified cyclodextrins, Pharmazie, 62, 55
Beni, 2007, Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities, Eur. J. Pharm. Sci., 30, 167, 10.1016/j.ejps.2006.10.008
Morales, 2007, Study of the interaction between S(−)bupivacaine and 2-hydroxypropyl-β-cyclodextrin, Int. J. Pharm., 331, 99, 10.1016/j.ijpharm.2006.09.054
Figeiras, 2007, Interaction of omeprazole with a methylated derivative of β-cyclodextrin: phase solubility, NMR spectroscopy and molecular simulations, Pharm. Res., 24, 377, 10.1007/s11095-006-9161-8
Al Omari, 2006, Sidenafil/cyclodextrin complexation: stability constants, thermodynamics and guest-host interactions probed by 1H NMR and molecular modeling studies, J. Pharm. Biomed. Anal., 41, 857, 10.1016/j.jpba.2006.01.055
Lahiani-Skiba, 2006, Solubility and dissolution rate of progesterone-cyclodextrin-polymer systems, Drug Dev. Ind. Pharm., 32, 1043, 10.1080/03639040600897093
Lee, 2007, Physicochemical characterization and bioavailability of a novel intestinal metabolite of ginseng saponin (IH901) complexes with β-cyclodextrin, Int. J. Pharm., 316, 29, 10.1016/j.ijpharm.2006.02.035
Uzqueda, 2006, Characterization of complexes between naftifine and cyclodextrins in solution and in the solid state, Pharm. Res., 23, 980, 10.1007/s11095-006-9903-7
Ventura, 2006, Physico-chemical characterization of disoxaril-dimethyl-β-cyclodextrin inclusion complex and in vitro permeation studies, Eur. J. Med. Chem., 41, 233, 10.1016/j.ejmech.2005.11.002
Perry, 2006, The binding interaction of synthetic ozonide antimalarials with natural and modified β-cyclodextrins, J. Pharm. Sci., 95, 146, 10.1002/jps.20525
Cappello, 2006, Improvement of solubility and stability of valsartan by hydroxypropyl-β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem., 54, 289, 10.1007/s10847-005-9004-y
Torne, 2006, Inclusion complexation of anti-HIV drug with β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem., 56, 253, 10.1007/s10847-006-9092-3
Shen, 2006, Determination of the inclusion complex between gossypol and β-cyclodextrin, Spectrochim. Acta, Part A, 65A, 169, 10.1016/j.saa.2005.09.045
Al Omari, 2006, Effect of buffer species on the inclusion complexation of acidic drug celecoxib with cyclodextrin in solution, J. Incl. Phenom. Macrocycl. Chem., 55, 247, 10.1007/s10847-005-9041-6
Jadhav, 2006, Interaction of valdecoxib with β-cyclodextrin: experimental and molecular modeling studies, J. Incl. Phenom. Macrocycl. Chem., 56, 261, 10.1007/s10847-006-9093-2
Pinto, 2005, Physico-chemical characterization of benzocaine-β-cyclodextrin inclusion complexes, J. Pharm. Biomed. Anal., 39, 956, 10.1016/j.jpba.2005.06.010
Tommasini, 2005, The inclusion complexes of hesperetin and its 7-rhamnoglucoside with (2-hydroxypropyl)-β-cyclodextrin, J. Pharm. Biomed. Anal., 39, 572, 10.1016/j.jpba.2005.05.009
Zheng, 2005, Physicochemical and structural characterization of quercetin-β-cyclodextrin complexes, J. Pharm. Sci., 94, 1079, 10.1002/jps.20325
Yap, 2005, Characterization of the 1,3-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis, Eur. J. Pharm. Sci., 25, 49, 10.1016/j.ejps.2005.01.021
Rajendrakumar, 2005, Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in the rat, Eur. J. Pharm. Biopharm., 60, 39, 10.1016/j.ejpb.2004.12.005
Larsen, 2005, Phase solubility and structure of the inclusion complexes of prednisolone and 6α-methyl prednisolone with various cyclodextrins, J. Pharm. Sci., 94, 507, 10.1002/jps.20192
Loftsson, 2005, Cyclodextrin solubilization of the antibacterial agents triclosan and triclocarban: effect of ionization and polymers, J. Incl. Phenom. Macrocycl. Chem., 53, 109, 10.1007/s10847-004-6048-3
El-Barghouthi, 2005, Host-guest interactions of risperidone with natural and modified cyclodextrins: phase–solubility, thermodynamics and molecular modeling studies, J. Incl. Phenom. Macrocycl. Chem., 53, 15, 10.1007/s10847-004-8212-1
Sinha, 2005, Complexation of celecoxib with β-cyclodextrin: characterization of the interaction in solution and in solid state, J. Pharm. Sci., 94, 676, 10.1002/jps.20287
Calabro, 2004, Effects of α- and β-cyclodextrin complexation on the physico-chemical properties and antioxidant activity of some 3-hydroxyflavones, J. Pharm. Biomed. Anal., 35, 365, 10.1016/j.jpba.2003.12.005
Mukne, 2004, Triamterene-β-cyclodextrin systems: preparation, characterization and in vivo evaluation, AAPS PharmSciTech, 5, 1, 10.1007/BF02830587
Sætern, 2004, Effect of hydroxypropyl-β-cyclodextrin-complexation and pH on the solubility of camptothecin, Int. J. Pharm., 284, 61, 10.1016/j.ijpharm.2004.07.014
Yanez, 2004, Spectrophotometric and electrochemical study of the inclusion complex between β-cyclodextrin and furnidipine, J. Pharm. Biomed. Anal., 35, 51, 10.1016/j.jpba.2003.12.015
Rawat, 2004, Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes, Eur. J. Pharm. Biopharm., 57, 263, 10.1016/j.ejpb.2003.10.020
Castro-Hermida, 2004, Anticryptosporidial activity of furan derivative G1 and its inclusion complex with β-cyclodextrin, J. Pharm. Sci., 93, 197, 10.1002/jps.10528
Yamamura, 2004, Factors controlling the complex architecture of native and modified cyclodextrins with dipeptide (Z–Glu–Tyr) studies by microcalorimetry and NMR spectroscopy: critical effects of peripheral bis-trimethylamination and cavity size, J. Am. Chem. Soc., 126, 14224, 10.1021/ja046612r
Aki, 2004, Multimodal inclusion complexes of ampicillin with β-cyclodextrin in aqueous solution, Thermochim. Acta, 416, 87, 10.1016/j.tca.2003.01.004
Rajendrakumar, 2004, Comparative study on co-ground products of rofecoxib with β-cyclodextrin and its sulfobutyl ether-7 derivative in solution and in the solid state, J. Incl. Phenom. Macrocycl. Chem., 49, 259, 10.1023/B:JIPH.0000048314.41966.65
Vlachou, 2003, Preparation and characterization of the inclusion complex of furosemide with hydroxypropyl-β-cyclodextrin, J. Biomater. Appl., 17, 197, 10.1177/0885328203017003557
Koontz, 2003, Formation of natamycin: cyclodextrin inclusion complexes and their characterization, J. Agric. Food Chem., 51, 7106, 10.1021/jf030332y
Waleczek, 2003, Phase solubility studies of pure (−)-α-bisbolol and chamomile essential oil with β-cyclodextrin, Eur. J. Pharm. Biopharm., 55, 247, 10.1016/S0939-6411(02)00166-2
Liu, 2003, Inclusion of acitretine into cyclodextrin: phase solubility, photostability and physicochemical characterization, J. Pharm. Sci., 92, 2449, 10.1002/jps.10495
Holvoet, 2003, Preparation and in-vivo release rate of fentanyl-cyclodextrin complexes for prolonged action in epidural analgesia, Int. J. Pharm., 265, 13, 10.1016/S0378-5173(03)00368-5
Rawat, 2003, Rofecoxib-β-cyclodextrin inclusion complex for solubility enhancement, Pharmazie, 58, 639
Illapakurthy, 2003, Interaction of artemisinin and its related compounds with hydroxypropyl-β-cyclodextrin in solution state: experimental and molecular-modeling studies, J. Pharm. Sci., 92, 649, 10.1002/jps.10319
Taneri, 2003, Influence of cyclodextrin complexation on the physicochemical and biopharmaceutical properties of ketoconazole, J. Incl. Phenom. Macrocycl. Chem., 47, 15, 10.1023/B:JIPH.0000003875.46691.f6
Chen, 2003, Inclusion complex of carprofen with hydroxypropyl-β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem., 46, 111, 10.1023/A:1025699207208
Barbato, 2003, Diclofenac/β-cyclodextrin binary systems: a study in solution and in the solid state, J. Incl. Phenom. Macrocycl. Chem., 46, 179, 10.1023/A:1026303516401
Tavornvipas, 2002, Some pharmaceutical properties of a new branched cyclodextrin, 6-O-α-(4-O-α-d-glucuronyl)-d-glucosyl-β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem., 44, 391, 10.1023/A:1023067232328
Tavornvipas, 2002, 6-O-α-(4-O-α-d-glucoronyl-d-glucosyl-β-cyclodextrin: solubilizing ability and some cellular effects, Int. J. Pharm., 249, 199, 10.1016/S0378-5173(02)00537-9
De Bie, 1998, Disposition of 14C-γ-cyclodextrin in germ-free and conventional rats, Regul. Toxicol. Pharmacol., 27, 150, 10.1006/rtph.1998.1219
Van Ommen, 2004, Disposition of 14C-α-cyclodextrin in germ-free and conventional rats, Regul. Toxicol. Pharmacol., 39, S57, 10.1016/j.yrtph.2004.05.011
Antlsperger, 1992, New aspects in cyclodextrin toxicology, 277
Matsuda, 1983, Acute toxicity study of γ-cyclodextrin (γ-CD) in mice and rats, Ogo Yakuri (Pharmacometrics),, 26, 287
2004, vol. 2